Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
PR Newswire•21/10/2026•07:30 ET
0
Key Highlights
- ➤Third-quarter sales $13.013 billion, up 14.5% reported and 7.0% comparable
- ➤Adjusted diluted EPS $1.42, up 9.2% year over year
- ➤Full-year adjusted diluted EPS guidance reaffirmed and tightened to $5.50-$5.55
- ➤Full-year comparable sales growth projected at approximately 6.0%
- ➤Diagnostics comparable sales rose 6.4%, while Medical Devices comparable sales increased 7.8%
Expert Statements
Robert B. Ford, Chairman and Chief Executive Officer of Abbott
“Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio.”
Robert B. Ford, Chairman and Chief Executive Officer of Abbott
“With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead.”
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance PR Newswire
* Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent * Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42 * Expands portfolio with key new product approvals ABBOTT PARK, Ill., Oct. 21, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2026.
Get started
Create a free account to read the full story.